[Molecular pharmacology of sarpogrelate].
Sarpogrelate, a 5-HT2A antagonist, is used clinically as a therapeutic agent for ischemic blood vessels. Thus, the present study was designed to evaluate the selectivity to 5-HT2 subtypes, to assess the pharmacological effect using porcine coronary arteries and to demonstrate the identification of the binding sites using molecular modeling. Sarpogrelate was higher selectivity to 5-HT2A than those of ketanserin, ritanserin or cyproheptadine and these results were supported by the computer modeling.
Nagatomo
Takafumi
T
Department of Pharmacology, Niigata University of Pharmacy and Applied Sciences, 5-13-2 Kamishinei-cho, Niigata 950-2081, Japan.
D000818:Animals; D003198:Computer Simulation; D003331:Coronary Vessels / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013386:Succinates / Q000494:pharmacology*; D013552:Swine
D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate